SureshSakkaraiRamalingamMDFACP, FASCO

Oncology • Atlanta, GA

Hematologic Oncology, Thoracic Cancer

Executive Director, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Ramalingam is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ramalingam's full profile

Already have an account?

Office
1365 Clifton Road NE
C-4014E
Atlanta, GA 30322
Phone(404) 778-5378

Fax(404) 778-5520
Is this information wrong?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
Wayne State University School of MedicineResidency, Internal Medicine, 1993 - 1996
Kilpauk Medical CollegeClass of 1992

Certifications & Licensure

GA State Medical License 2007 - 2023
PA State Medical License 2000 - 2008
MI State Medical License 1995 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor Start of enrollment: 2004 May 01
Completed
Phase 1
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Aug 01
Completed
Phase 2
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Start of enrollment: 2005 Jun 01
Completed
Phase 2
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors Start of enrollment: 2005 Jul 01
Completed
Phase 1
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Start of enrollment: 2006 Jun 01
Completed
Phase 2
Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 Nov 01
Completed
Phase 1
Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Nov 01
Terminated
Phase 1, Phase 2
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2007 May 01
Completed
Phase 2
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction Start of enrollment: 2007 Jun 01
Completed
Phase 1
Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Aug 12
Active, not recruiting
Phase 3
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies Start of enrollment: 2012 May 01
Withdrawn
Phase 1
Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) Start of enrollment: 2018 Jul 19
Recruiting
Phase 3
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 12
Recruiting
Phase 1, Phase 2
GEN1046 Safety Trial in Patients With Malignant Solid Tumors Start of enrollment: 2019 May 14
Recruiting
Phase 1, Phase 2
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Start of enrollment: 2019 Oct 08
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
Zhen Chen, Karin A. Vallega, Haiying Chen, Jia Zhou, Suresh S. Ramalingam, Shi-Yong Sun> ;Pharmacological Research. 2022 Jan 1
1 citations
Surgical Outcomes for Early-Stage Non-Small Cell Lung Cancer at Facilities with Stereotactic Body Radiation Therapy Programs.
Yusef A. Syed, William A. Stokes, Manali Rupji, Yuan Liu, Onkar V. Khullar, N. Sebastian, Kristin Higgins, Jeffrey D. Bradley, Walter J. Curran, Suresh S. Ramalingam, ...> ;Chest. 2021 Nov 14
10 citations
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
Patrick M. Forde, Valsamo Anagnostou, Z. Sun, Suzanne E. Dahlberg, Hedy L. Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z. Dudek, Hossein...> ;Nature Medicine. 2021 Nov 8
19 citations
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 O...
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria Rosario Garcia Campelo, Enrique...> ;JAMA Oncology. 2021 Oct 14
9 citations
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz-Ares, Suresh S. Ramalingam, Tudor-Eliade Ciuleanu, Jong Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio,...> ;Journal of Thoracic Oncology. 2021 Oct 12
3 citations
Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib.
Zhen Chen, Danlei Yu, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun> ;Oncogene. 2021 Oct 11
4 citations
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Suresh S. Ramalingam, Eddie Thara, Mark M. Awad, Afshin Dowlati, Basir Haque, Thomas E. Stinchcombe, Grace K. Dy, David R. Spigel, Sharon Lu, Nithya Iyer Singh, Yongqi...> ;Cancer. 2021 Sep 3
4 citations
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
Suresh S. Ramalingam, Silvia Novello, Salih Zeki Guclu, Dmitry Bentsion, Zanete Zvirbule, Mária Szilasi, R. Bernabé, Konstantinos N. Syrigos, Lauren Averett Byers, Phi...> ;Journal of Clinical Oncology. 2021 Aug 26
1 citations
Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
Lei Huang, Ramireddy Bommireddy, Luis E. Munoz, Rohini N. Guin, Changyong Wei, Amanda Ruggieri, Ashwathi P. Menon, Xiaoxian Li, Mala Shanmugam, Taofeek K. Owonikoko, S...> ;PLOS ONE. 2021 Aug 19
3 citations
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP s...
Natasha B. Leighl, Mary W. Redman, Naiyer A. Rizvi, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, James L. Wade, William J. Irvin, Sreekanth Reddy, Jeffrey Cra...> ;Journal for ImmunoTherapy of Cancer. 2021 Aug 1
1 citations
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiothera...
Dirk De Ruysscher, Suresh S. Ramalingam, James J. Urbanic, David E. Gerber, Daniel S.W. Tan, Junliang Cai, Ang Li, Solange Peters> ;Clinical Lung Cancer. 2021 Jul 19
4 citations
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Scott N. Gettinger, Mary W. Redman, Lyudmila Bazhenova, Fred R. Hirsch, Philip C. Mack, Lawrence H. Schwartz, Jeffrey D. Bradley, Thomas E. Stinchcombe, Natasha B. Lei...> ;JAMA Oncology. 2021 Sep 1
1 citations
Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Wen Zhao, Danlei Yu, Zhen Chen, Weilong Yao, Jin Yang, Suresh S. Ramalingam, Shi-Yong Sun> ;Cancer Letters. 2021 Oct 28
Cancer matters: Now more than ever!
Suresh S. Ramalingam> ;Cancer. 2021 Jul 1
3 citations
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Guoqing Qian, Jianping Guo, Karin A. Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh S. Ramalingam, Taofeek K. Owonikoko, Wenyi Wei, S...> ;Molecular Cancer Research. 2021 Jun 28
5 citations
Advances in Immunotherapy and Implications for Current Practice in Non-Small-Cell Lung Cancer.
Conor E. Steuer, Suresh S. Ramalingam> ;Organic Process Research & Development. 2021 Jun 25
114 citations
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barle...> ;The New England Journal of Medicine. 2021 Jun 4
1 citations
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504).
Saad A. Khan, Z. Sun, Suzanne E. Dahlberg, Jyoti Malhotra, Roger Keresztes, Chukwuemeka Ikpeazu, Patrick Ma, Suresh S. Ramalingam, Rathi N. Pillai> ;JTO clinical and research reports. 2021 May 1
Co-Occurrence Conundrum: Brain Metastases from Lung Adenocarcinoma, Radiation Necrosis, and Gliosarcoma
David C. Qian, Brent D. Weinberg, Stewart G. Neill, Abigail L. Goodman, Jeffrey J. Olson, Alfredo Voloschin, Suresh S. Ramalingam, Hui-Kuo Shu> ;Case Reports in Oncology. 2021 Jan 1
25 citations
An expanded universe of cancer targets.
William C. Hahn, Joel S. Bader, Theodore P. Braun, Andrea Califano, Paul A. Clemons, Brian J. Druker, Andrew J. Ewald, Haian Fu, Subhashini Jagu, Christopher J. Kemp, ...> ;Cell. 2021 Mar 4
1 citations
A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.
John M. Varlotto, Z. Sun, Bonnie Ky, Jenica N. Upshaw, Sharyn I. Katz, Thomas J. Fitzgerald, Heather A. Wakelee, Maximilian Diehn, David A. Mankoff, Christine Lovely, ...> ;Oncologist. 2021 Jun 1
13 citations
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
Ying Cheng, Yong He, Wei Li, Helong Zhang, Qing Zhou, Bu-Hai Wang, Chunling Liu, Andrew Walding, M. Saggese, X. Huang, Minhao Fan, Jia Wang, Suresh S. Ramalingam> ;Targeted Oncology. 2021 Feb 5
Erratum: GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
Junghui Koo, Xuerong Wang, Taofeek K Owonikoko, Suresh S Ramalingam, Fadlo R Khuri, Shi-Yong Sun> ;Oncotarget. 2021 Feb 2
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
Rathi N. Pillai, Suresh S. Ramalingam, Meena Thayu, Patricia Lorenzini, Diana A. Alvarez Arias, Christopher Moy, Natalie Hutnick, Roland Elmar Knoblauch, Huaibao Feng,...> ;JTO clinical and research reports. 2021 Feb 1
2 citations
Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
Conor E. Steuer, Opeyemi Jegede, Suzanne E. Dahlberg, Heather A. Wakelee, Steven M. Keller, William J. Tester, David R. Gandara, Stephen L. Graziano, Alex A. Adjei, Ch...> ;Journal of Thoracic Oncology. 2021 Jun 1
Join now to see all

Journal Articles

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S Hong, Marwan G Fakih, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Adrian Sacher, Crystal S Denlinger, John C Krauss, Andrew L Coveler, Suresh S Rama..., The New England Journal of Medicine
Concurrent Chemoradiotherapy with Weekly Versus Triweekly Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Comparative Analysis
Rathi Pillai, Fadlo R Khuri, Nabil F Saba, Conor Steuer, Suchita Pakkala, Kristin Higgins, Jonathan J Beitler, Suresh S Ramalingam, Brandon Twardy, Kelly Schrapp, Taof..., Head & Neck
Targeted Sequencing and Intracranial Outcomes of Patients with Lung Adenocarcinoma Brain Metastases Treated with Radiotherapy
Gabriel L Sica, Matthew J Ferris, Walter J Curran, Shannon Kahn, Suresh S Ramalingam, Pretesh R Patel, Rathi N Pillai, Robert H Press, Jim Zhong, Conor E Steuer, Taofe..., Cancer
Predictive Biomarkers for Response to EGFR-Directed Monoclonal Antibodies for Advanced Squamous Cell Lung Cancer
D R Spigel, E S Kim, S S Ramalingam, M A Socinski, C Obasaju, C J Langer, R B Natale, P D Bonomi, H Wakelee, Annals of Oncology
Join now to see all

Lectures

ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.
2019 ASCO Annual Meeting - 6/1/2019

Other

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung Cancer
Suresh Ramalingam, MD, Op-Med
https://www.doximity.com/articles/35d1fb9e-f71f-4645-839f-870e7b27ebe0
UpToDate, Wolters Kluwer Health - 2012-10-04

Authored Content

How Immunotherapy Is Dramatically Changing Treatment for Non-Small and Small Cell Lung CancerOctober 2018

Press Mentions

Lung Cancer Therapy Makes Major Advances Lung Cancer Therapy Makes Major AdvancesOctober 10th, 2019
Ramalingam Highlights Immunotherapy Advances in NSCLCFebruary 22nd, 2018
Promoting Physician Wellness: An Overview of ASCO InitiativesJune 25th, 2017
Join now to see all